NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--June 15, 2006--Television stations across the country recently interviewed Dr. John Rothman, Vice President of Clinical Development for Advaxis, Inc. (OTCBB: ADXS - News), a developer of Listeria-based cancer vaccines. These interviews were part of the Company’s extensive program to help educate the public on the differences between the current prophylactic or preventative vaccines and next generation therapeutic vaccines being developed by Advaxis.
